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Heart-type fatty acid binding- protein (H-FABP) was introduced in 1988 as a potential novel biochemical marker 
for the early diagnosis of acute myocardial infarction 
(AMI).1 This was soon confirmed by many other 
studies.2-7 Under normal conditions, H-FABP is not 
present in plasma or interstitial fluid, but is released 
into the blood upon cardiac cellular injury. The 
H-FABP is released into plasma within 2 hours after 
symptom onset and is reported to peak at about 
4-6 hours and to return to normal base line level 
in 20 hours. Within the period of 30-210 minutes 
after symptom onset, H-FABP has > 80% sensitivity 
for the diagnosis of AMI.4-5 Within the interval of 
0-6 hours after symptom onset, the other cardiac 
markers such as creatine kinase (CK), CK-muscle 
and brain (MB) (mass or activity), cardiac troponin 
I (cTnI) and cardiac troponin T (cTnT) will only 
be starting to accumulate in the plasma, and their 
sensitivity has been reported to be around 64%.8 
The exact route(s) of excretion of H-FABP from the 
circulation is not fully understood. As suggested 
by previous studies, the kidney may be the major 
route of excretion of H-FABP from circulation.4,6,9 
The effect of disease states and in particular kidney 
disease on the renal handling of H-FABP has not 
yet been fully evaluated. The aim of this study was 
to compare the effect of renal failure on the level of 
H-FABP and cTnT concentrations.
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 في طبارلا نيهدلا بلقلا ضحم ينتورب لدعم سايق
  يولكلا شفلا نم نوناعي نيذلا ىضرلما لصم
سكوف ثيك ،مايليو تنرب ،يداهلا ظيفح
 ريغ .ةيبلق ةطلج دوجو ىلع ةلادلا ةركبلما ةيويلحا - ةيئايميكلا تاملاعلا دحأك 1988 ماع طبارلا ينهدلا بلقلا ضمح ينتورب زتلاج فشتكا :فدهلا :صخللما 
 طبارلا ينهدلا بلقلا ضمح ينتورب زيكرت ىلع يولكلا لشفلا ريثأت نراقت ةساردلا هذه .نلآا ىتح فاو لكشب هتسارد متي مل ينتوربلا اذه ىلع ىلكلا ضارمأ ريثأت نإ
 حوارتت (لاجر ةرشعو ءاسن تس) نمزم يولك لشف نم نوناعي اضيرم 16 نم ةنوكم ةعومجم ىلع ةساردلا تلمتشا :ةقيرطلا .مدلا يف (ت) بلقلا يننوبورت و
 531.3   و رتل / لوميلم  9.6 ± 19 وه ةعوملمجا هذه يف يننتايركلا و ايرويلا لدعم :جئاتنلا .يرود لكشب ىلك ليسغ جلاع نوقلتيو  ،ةنس 70 - 30 ينب مهرامعأ
 بلقلا يننوبورت ناك كلذكو .رتل / مارجوركيام (53.3 ±  81 )ىضرلما لك دنع اعفترم طبارلا ينهدلا بلقلا ضمح ينتورب ناك .يلاوتلا ىلع رتل / لوميلم 231.2 ±
 مارجوركيام 0.3 نم رثكأ و ،)31%  (ىضرم ةسمخ يف رتل / مارجوركيام 0.2 نم رثكأ و ، ) 50% (ىضرم ةينامث يف رتل / مارجوركيام 0.1 نم رثكأب اعفترم (ت)
 ةيبلقلا ةطللجا صيخشت ىلع (ت) بلقلا يننوبورت و طبارلا ينهدلا بلقلا ضمح ينتورب ةردق نإ ىلإ ريشت ةساردلا هذه :ةصلالخا .)6% ( دحاو ضيرم يف رتل /
 .دودحم يولك لشف دوجو يف
 .يولك لشف ،(ت) بلقلا يننوبورت ،طبارلا ينهدلا بلقلا ضمح ينتورب :تاملكلا حاتفم
abstract: Objectives: Heart-type fatty acid binding-protein (H-FABP) has been reported to be a potential novel 
biochemical marker for the early diagnosis of acute myocardial infarction (AMI). The effect of kidney diseases on the 
renal handling of H-FABP has not yet been fully evaluated. The aim of this study was to compare the effect of renal failure 
on the level of H-FABP and cardiac troponin (cTnT) concentrations. Methods: The study population was a small group 
of 16 patients with renal failure (6 females, 10 males aged 30-70 years) on routine regular haemodialysis or peritoneal 
dialysis. Results: The mean ±SD of serum urea and creatinine concentration in this group of patients was 19 ±9.6 mmol/L 
and 531.3 ±231.2 mmol/L respectively. H-FABP was increased in all 16 patients (81 ±53.3µg/L). The cTnT was increased 
≥ 0.1µg/L in 8 patients (50%), ≥ 0.2µg/L in 5 patients (31.3%), and ≥ 0.3µg/L in 1 patient (6%). Conclusion: The diagnostic 
efficiency of H-FABP and cTnT for the diagnosis of AMI in the presence of renal failure may be limited and such patients 
may have high levels even in the absence of AMI.
Keywords: Heart-type fatty acid-binding protein; Cardiac troponin T; Renal failure.
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Methods 
The study population consisted of a small group of 
16 patients with renal failure (6 females, 10 males, 
aged between 30-70 years) without evidence of 
acute coronary syndromes. These patients were on 
routine regular haemodialysis or peritoneal dialysis, 
and were recruited from the Renal Unit at the Royal 
Infirmary of Edinburgh, U.K. These patients had a 
range of diseases that were commonly seen in the 
renal unit including chronic glomerulonephritis 
(3 patients), interstitial nephritis (3 patients), 
adult dominant polycystic kidney disease (2 
patients), hypertensive and diabetic nephropathy (8 
patients). Peripheral blood samples were collected 
in white Starstedt Monovette vacutainer tubes by 
venepuncture. The blood samples (5mls) were taken 
through a peripheral line (intravascular access). 
The extracted samples were allowed to clot at 
room temperature for 1 hour and then centrifuged 
at 4°C, and the resulting serum was divided into 
small aliquots and frozen at -70°C until analysis. 
The H-FABP was analysed by an enzyme linked 
immunosorbent assay method using commercially 
available assays (Hycult, Cambridge). The analytical 
sensitivity of H-FABP, presented as mean ±2SD, was 
0.206 ±0.047g/L.10 The cTnT was analysed on Elecsys 
2010 using commercial assays (Roche, Germany). 
Ethical approval was obtained from the local ethical 
committee and an informed consent was obtained 
from each patient before beginning the study. The 
study complies with the Declaration of Helsinki.
Results  
The reference ranges quoted by the manufacturer 
for cTnT (< 0.01µg/L) and H-FABP (< 5µg/L) assays 
were validated by assaying the normal ranges of 20 
healthy blood donors samples (healthy blood donor 
controls: 10 males and 10 females, mean age SD = 
63.8 ±8.01 years (median = 65 years [range 53-75 
years]). The mean ±SD concentrations of cTnT and 
H-FABP were 0.011 ±0.002µg/L, and 6.86 ±2.21 
µg/L respectively. The coefficients of variation (CVs) 
of the assays were always < 10%.
The serum urea and creatinine concentration in 
this group of patients was 19 ±9.6 mmol/L and 531.3 
±231.2 µmol/L respectively. H-FABP was increased 
in all 16 patients (mean = 81 ±53.3µg/L [range 24-
173µg/L]). The cTnT was increased ≥0.1µg/L in 
8 patients (50%), ≥ 0.2µg/L in 5 patients (31.3%), 
and ≥ 0.3µg/L in 1 patient (6%). In the remaining 8 
patients, cTnT was 0.069 ±0.023µg/L (range 0.021-
0.087µg/L). There were no correlations between the 
concentration of either urea or creatinine and the 
concentration of H-FABP and cTnT. There was a 
positive correlation between the concentrations of 
cTnT and H-FABP (r = 0.569, p < 0.02). 
Discussion 
H-FABP is a small (15 Kda) soluble non-enzyme 
protein. It is composed of 132 amino acids. It is 
one of the most abundant proteins in the heart 
and comprises 5-15% of the total cytosolic protein 
pool in the aqueous cytoplasm. H-FABP exists in 
high concentrations in the heart only. However, 
this protein is not totally cardiac specific and 
occurs in other tissues although in much lesser 
concentrations.11 It is present in skeletal muscles 
in concentrations varying between 0.05-0.2mg/g 
wet weight of tissue, depending on the muscle fibre 
type studied.2 It has also been reported in very low 
concentrations in tissues like the kidney, aorta, 
testes, mammary glands, placenta, brain, adrenal 
glands, adipose tissue, and stomach.11 Preliminary 
but promising applications of these proteins have 
been demonstrated for liver rejection, viability 
selection of kidneys from non-heart-beating donors 
(NHBD), inflammatory and ischaemic bowel disease, 
traumatic brain injury and in the prevention of 
muscle injury in trained athletes.12 The cytoplasmic 
to vascular concentration of H-FABP is of the order 
of 200,000:1. The plasma or serum concentration of 
H-FABP under normal conditions is < 5µg/L.1 This 
makes the plasma estimation of H-FABP a suitable 
indicator for the early detection and quantification 
of myocardial tissue injury. A rise in serum and 
urine H-FABP concentrations above normal values 
is seen in patients presenting with AMI as early as 
1.5 hours after symptom onset.6 Studies in animals 
have also shown decreased myocardial tissue 
content and rising plasma and urine concentrations 
of H-FABP very early after coronary artery ligation.9 
Some of the more recent studies have questioned 
the value of these early markers (H-FABP and 
myoglobin) when compared with specific markers 
like cTnI.13 
The reason for elevated H-FABP in our study 
of patients with chronic kidney disease (CKD) on 
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regular dialysis is not clearly understood. These 
patients did not have any evidence of myocardial 
injury clinically (neither by history nor by 
electrocardiogram criteria). This may simply be due 
to lack of clearance by the diseased kidneys, because 
H-FABP is totally cleared by the kidneys. Uraemic 
cardiomyopathy is a recognised complication of 
CKD and it may be possible that some of the leakage 
of H-FABP could reflect sub-clinical myocardial 
injury. The release of H-FABP may be from other 
tissues containing this protein which are affected 
by CKD or by drugs used in management e.g. brain 
or bowel. H-FABP circulates for a longer time (> 25 
hours) after AMI in the presence of renal failure.4 
Gorski et al. reported that H-FABP and myoglobin 
concentrations were both significantly elevated 
in patients with renal failure. The concentrations 
of these markers were not affected by dialysis. In 
addition, the myoglobin to H-FABP ratio in this 
group was similar to the ratio found in patients with 
myocardial infarction.14 
The cTnT (34 KDa) was first introduced in 1989 
as a marker for AMI. The upper limit for cTnT has 
been reported as < 0.1µg/L, but concentrations 
between 0.03-0.1µg/L may also have significance 
as markers of an adverse outcome.15 This marker 
appears in the serum within 12 hours after 
symptom onset in patients with AMI. Elevated 
cTnT in patients with unstable angina is associated 
with poor prognosis.16 The increase correlates 
well with the severity of coronary artery lesions as 
determined by angiography. The cTnT marker is a 
sensitive and specific marker of myocardial injury. 
However, elevated cTnT concentrations have been 
reported in a significant numbers of patients with 
chronic renal failure. These levels do not seem to be 
affected by haemodialysis, with elevations persisting 
after treatment.17-18 Nadheem et al. have shown that 
cTnT had lower sensitivity and specificity for the 
diagnosis of AMI compared with cTnI in patients 
with CKD on dialysis. They also demonstrated 
that increased cTnT was associated with all causes 
mortality during two years follow-up.19 A significant 
numbers of patients in our study had elevated cTnT 
concentrations. These elevated levels may be due 
to a combination of slow clearance and/or uraemic 
cardiomyopathy. 
In a separate study, we used the following 
concentrations to define the presence of AMI: 
H-FABP ≥ 12.5µg/L (sensitivity = 91.4%, specificity 
= 86%); cTnT ≥ 0.1µg/L (Sensitivity = 76.4%, 
Specificity = 99%). These cut-off concentrations 
for the diagnosis of AMI were based on receiver 
operating characteristices (ROC) analysis between 
patients with AMI (n = 45 patients) and patients 
without AMI (stable angina, atypical angina, 
normal controls, n = 70 patients).20 Based on 
these cut-off values, all 16 patients would meet 
the criteria for the diagnosis of AMI if we used 
H-FABP concentrations. Also significant numbers 
(8 patients, 50%) had raised values ≥ 0.1µg/L. 
Conclusion
This study indicates that the efficiency of H-FABP 
for the diagnosis of AMI in the presence of renal 
failure is limited. The presence of renal failure may 
also interfere with the specificity of cTnT for the 
detection of myocardial injury. This interference 
should be borne in mind when interpreting the result 
of these two markers in patients with acute coronary 
syndromes in the presence of renal impairment. 
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